In contrast, in this study, we showed that afatinib could reverse the drug resistance and enhance the cytotoxicity of conventional anticancer drugs in ABCG2-overexpressing cancer cells by a dual inhibition of ABCG2. This evidence concerns the gene ABCG2 and cancer.